Design Therapeutics, Inc. DSGN Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $0— | $0— | —— | —— | ||
| $59.13M+33.3% | $44.35M-22.3% | $57.06M+17.4% | $48.61M+96.2% | ||
| $20.34M+12.8% | $18.03M-14.6% | $21.13M+11.3% | $18.98M+71.7% | ||
| $79.47M+27.4% | $62.38M-20.2% | $78.19M+15.7% | $67.59M+88.6% | ||
| -$79.47M-27.4% | -$62.38M+20.2% | -$78.19M-15.7% | -$67.59M-88.6% | ||
| —— | —— | $11.33M+164% | $4.29M+1,338% | ||
| -$69.79M-40.7% | -$49.59M+25.8% | -$66.86M-5.6% | -$63.31M-78.2% | ||
| -$1.22-38.6% | -$0.88+26.7% | -$1.20-5.3% | -$1.14-32.6% | ||
| -$78.85M-27.6% | -$61.79M+20.4% | -$77.65M-15.6% | -$67.19M-88.2% | ||
| -$79.47M-27.4% | -$62.38M+20.2% | -$78.19M-15.7% | -$67.59M-88.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Design Therapeutics, Inc. profitable?
- Design Therapeutics, Inc. is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -3663.7% net margin.
- What is Design Therapeutics, Inc.'s earnings per share?
- Design Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.20.
- Where does Design Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.